Translate this page into:
Solvent free synthesis of 3,4-dihydropyrimidine-2-(1H)-ones/thiones catalyzed by N,O-bis(trimethylsilyl)acetamide and dicyclohexyl carbodimide
⁎Corresponding authors: Tel.: +91 9032837383; fax: +91 891 2713813 (Y.L.N. Murthy). abdulrazzack1@gmail.com (Abdul Rajack)
-
Received: ,
Accepted: ,
This article was originally published by Elsevier and was migrated to Scientific Scholar after the change of Publisher.
Peer review under responsibility of King Saud University.
Abstract
We report herein, the usage of N,O-bis(trimethylsilyl)acetamide (BSA) and dicyclohexyl carbodimide (DCC) as two new catalysts for three component condensation of an aldehyde, ethyl acetoacetate and urea/thiourea under solvent free conditions at 100 °C to afford the corresponding 3,4-dihydropyrimidine-2-(1H)-ones/thiones (DHPMs) in good to excellent yields. A comparative study of these two catalysts was made and presented.
Keywords
N,O-Bis(trimethylsilyl)acetamide
Dicyclohexyl carbodimide
Solvent free
3,4-Dihydropyrimidinones
3,4-Dihydropyrimidithiones
1 Introduction
In the recent decades, the developments of multi component condensations (Ugi et al., 1994; Domling, 2006) (MCCs) are of increasing importance in organic and medicinal chemistry for modern drug discovery. It was soon established that DHPMs exhibit similar therapeutic and pharmacological profile to 1,4 dihydropyridines (DHPs) calcium channel modulator of the nefidine (Domling, 1998; Plunlett and Ellman, 1997; Schreiber, 2000). From the past two decades synthesis of DHPMs and their derivatives being a hot area of research due to their wide spectrum of biological activities (Bryzgalov et al., 2006; Holla et al., 2004; Zorkun et al., 2006; Kappe, 1993, 1998, 2000a,b; Chitra et al., 2010; Atwal et al., 1991; Rovnyak et al., 1992), including antibacterial, antiviral, antitumor, anti-inflammatory, antiarrhythmic activity, antifungal activities, and antihypertensive as well as the most potent Ca2+ channel blockers (Rovnyak et al., 1995; Aswal et al., 1990). Recently, inhibitors of the fatty acid transporter FATP4 (Christopher et al., 2006), one of the DHPMs derivative monastrol has emerged as a new chemical tool for investigating human mitotic kinesin Eg5 (Emmanuel et al., 2007) motor protein inhibitor for the development of anticancer drugs. Furthermore, the marine alkaloids attributed to the dihydro pyrimidinones moiety in the structure isolated from natural marine sources such as crambine, batzelladine B (potent HIVgp-120CD4 inhibitors) (Rama Rao et al., 1995).
The classical Biginelli reaction (Biginelli et al., 1888); Kolosov et al., 2009) is the MCCs of aldehyde, ethyl acetoacetate and urea/thiourea refluxed at100 °C in ethanol, in the presence of acetic acid for 8 h. Several synthetic methodologies such as solvent free (Weike, 2005; Bahrami et al., 2009; Besoluk et al., 2008; Jing et al., 2009), ultrasounds (Yadav et al., 2001), ionic liquids (Sushilkumar et al., 2004; Jiajian, 2001), microwave synthesis (Kalyan Kumar, 2011; Kidwai et al., 2002; Khabazzadeh et al., 2008), Green approach synthesis (Ranu et al., 2002; Subhas et al., 2003; Rafiee and Jafari, 2006; Zheng-Jun et al., 2009; Mridula et al., 2010), phase-transfer catalysis (Bahar, 2009), baker's yeast (Atu and Ram, 2007), Brønsted acids (Yang et al., 2007; Shutalev and Sivova, 1998; Renwei, 2006), Brønsted bases (Zhi-Liang et al., 2010), Lewis acids (Ramalingan et al., 2008; Paraskar et al., 2003; Kumar et al., 2001; Anil et al., 2007; Ma et al., 2000; Brindaban et al., 2000; Zhua, 2004; Surya et al., 2005; Hamid Reza et al., 2009), were developed to synthesize the 3,4 dihydro pyrimidinones/thiones. Out of all these methodologies to the best of our knowledge, there are two reports employing (PPh3) as a Lewis base (Debache et al., 2008). Herein, we report two new catalysts viz. (a) BSA (N,O-bis-(trimethylsilyl)acetamide) (b) DCC (dicyclohexyl carbodimide) for the synthesis of DHPMs under solvent free conditions at 100 °C, in an efficient way, good to excellent yields are obtained (Scheme 1).Synthesis of 3,4-dihydropyrimidinones/thiones catalyzed by BSA or DCC under solvent free conditions.
2 Results and discussions
BSA and DCC are the two good moisture absorbents. These two reagents were employed individually as a catalyst in the Biginelli reaction to produce DHPMs from aromatic aldehyde, ethyl acetoacetate and urea (4a-1 to 4j-1 and 4a-3 to 4j-3) or thiourea (4a-2 to 4j-2 and 4a-4 to 4j-4). In an initial endower the reaction was performed with 10 mole % of catalyst at RT in different solvents viz. ethanol, methanol, tetrahydrofuran, t-butanol, dioxan, acetonitrile and under solvent free conditions. Even after 24 h the reaction was not moved at RT, when the reaction temperature was raised to 100 °C after 24 h only 20–30% of the product was obtained under solvent free and catalyst free conditions. In the presence of BSA or DCC catalyst yielded better results with low reaction times under solvent free conditions. To optimize the amount of the catalyst we have carried out the reaction with various mole % of the catalysts. However there is no recognizable change in either % of yield or the reaction time by the increased amounts in catalysts over 10 mol % of both BSA and DCC (Table 1). To elaborate the catalysts efficiency we have examined the same reaction with other Brønsted bases, Lewis bases and Lewis acids under solvent free conditions the results are recorded in (Table 2). To define the scope and limitations, the efficiency of the catalysts (BSA and DCC) was examined with several aldehydes, ethyl acetoacetate and urea/thiourea. Between these two catalysts, the best results are produced with BSA. The final product (DHPMs) yields affected by the substitutions in the benzene ring, electron withdrawing groups like nitro groups leads relatively higher yields than electron donating groups like alkyl, alkoxy and hydroxy groups (Table 3).
Entry
Solvent
Mole % of BSA/DCC
Time (h)
Yield (%)
X = O
X = S
1
EtOH
10
20
50a
47b
46a
42b
2
MeOH
10
20
47a
45b
35a
39b
3
THF
10
18
20a
27b
13a
17b
4
Dioxan
10
24
20a
15b
16a
13b
5
CH3CN
10
24
30a
33b
32a
32b
6
Solvent free
05
3–4
30a
15b
43a
12b
7
Solvent free
10
3–4
80a
71b
57a
54b
8
Solvent free
15
3–4
82a
68b
55a
51b
9
Solvent free
20
3–4
81a
70b
56a
55b
Entry
Catalyst
Time (h)
Yield (%)
1
t-BuOK
10–12
57a
55b
2
BSA
1.2–4
80a
57b
3
DCC
1.3–4
71a
54b
4
PPh3
10–12
30a
29b
5
BF3et2O
6–8
43a
40b
6
AlCl3
8–10
40a
40b
7
Catalyst free
15–20
30a
20b
Entry
R-CHO
Catalyst
x
Product
Time (min)
Yielda (%)
Mp found
Mp reference
1
BSA
O
4a-1
200
80
182–183b
S
4a-2
260
54
180–181c
184–186 (Besoluk et al., 2008)
O
4a-3
230
71
183–184(Besoluk et al., 2008)
S
4a-4
260
57
2
BSA
O
4b-1
140
85
S
4b-2
180
72
172–173b
175–177 (Bahrami et al., 2009)
DCC
O
4b-3
170
83
210–212c
212–214 Bahar, 2009
S
4b-4
130
75
3
BSA
O
4c-1
140
78
S
4c-2
170
66
201–202b
202–20318a
DCC
O
4c-3
150
72
150–152c
152–153 (Khabazzadeh et al., 2008)
S
4c-4
180
61
4
BSA
O
4d-1
170
90
S
4d-2
200
81
208–210b
210–212 (Debache et al., 2008)
DCC
O
4d-3
170
81
182–183c
184–185 (Debache et al., 2008)
S
4d-4
200
80
5
BSA
O
4e-1
100
87
S
4e-2
80
85
210–212b
214–215 (Besoluk et al., 2008)
DCC
O
4e-3
130
86
218–220c
219–221 (Besoluk et al., 2008)
S
4e-4
120
74
6
BSA
O
4f-1
180
88
S
4f-2
220
79
200–202b
204–205 (Besoluk et al., 2008)
DCC
O
4f-3
190
89
161–162c
163–164 (Besoluk et al., 2008)
S
4f-4
240
75
7
BSA
O
4g-1
140
90
S
4g-2
110
75
229–230b
230–232 (Besoluk et al., 2008)
DCC
O
4g-3
90
85
204–205c
206–207 (Besoluk et al., 2008)
S
4g-4
110
73
8
BSA
O
4h-1
260
85
S
4h-2
220
87
234–235b
237–238 (Slimi et al., 2016)
DCC
O
4h-3
200
84
192–194c
193–195 (Mridula et al., 2010)
S
4h-4
150
76
9
BSA
O
4i-1
240
85
S
4i-2
260
75
180–181b
180–18218b
DCC
O
4i-3
290
78
200–201c
202–204 (Subhas et al., 2003)
S
4i-4
300
72
10
BSA
O
4j-1
230
90
S
4j-2
260
78
200–202b
202–204 (Mridula et al., 2010)
DCC
O
4j-3
230
82
200–201c
200–205 (Mridula et al., 2010)
S
4j-4
240
75
The reaction may proceed via acylimine intermediate, formed by the reaction of the aldehyde and urea/thiourea. Subsequent addition of β-ketoester enolate to the acylimine, followed by cyclization and dehydration by the catalysts BSA or DCC, afforded the corresponding 3, 4-dihydropyrimidinones/thiones. Schemes 2 and 3 were the deniable mechanisms in the synthesis Biginelli 3,4-dihydropyrimidinones/thiones. More recently similar kind of mechanism was explained by Debache et al. (2008), Slimi et al. (2016), Folkers et al. (1932), Mamaev and Dubovenko (1970) and Valverde et al. (2001).Plausible mechanism for the synthesis of 3,4-dihydropyrimidinones/thiones with DCC.
Plausible mechanism for the synthesis of 3,4-dihydropyrimidinones/thiones with BSA.
3 Conclusion
To sum up, we have developed novel methodologies for the synthesis of DHPMs carried out by BSA/DCC under solvent free conditions, excellent catalysts for one pot synthesis of dihydropyrimidinones/thiones under solvent free conditions, short reaction time, high yields of products, simple work up procedures and easy isolation making it an important supplement to the existing methods. Further, we are studying the scope of these catalysts to the other organic multicomponent reactions.
4 Experimental
4.1 General procedure for synthesis of 3,4-dihydropyrimidinones/thiones under solvent free conditions
Aromatic aldehyde (0.01 moles), ethyl acetoacetate (0.012 moles) and urea/thiourea (0.01 moles) were stirred at 100 °C in the presence of BSA/DCC (10 mol %) for 110–300 min, the reaction was monitored by thin layer chromatography (TLC) [6:4 hexane–ethyl acetate]. After the completion of the reaction the reaction mixture was cooled and washed with ice cooled water, the separated solid was filtered and dried in vacuum, the solid product passed over a column of silica gel (60–100 mesh), finally recrystallized from alcohol to afford the desired product in pure form. Melting points were measured on Polmon melting point apparatus Mp 96. IR spectra were recorded on a Shimadzu IR Affinity-1. 1H and 13C NMR spectra were recorded on a Bruker DRX 200 spectrometer and 50 MHz, respectively. NMR spectra were obtained on solutions in CDCl3 and DMSO-d6. Mass spectra were recorded on water XEVO QTof mass spectrometer.
4.2 4-(3-Hydroxy-phenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylicacid ethyl ester (4a-2)
Mp 182–183 °C; IR (KBr): 3423, 3095, 2920, 2823, 1719, 1658, 1517 cm−1; 1H NMR (200 MHz, DMSO-d6): δ 1.16 (t, J = 7.2 Hz, 3H OCH2CH3), 2.21 (s, 3H, CH3), 4.02 (q, J = 7.2 Hz, 2H, OCH2CH3), 5.17 (d, J = 3.0 Hz, 1H, CH-Ar), 6.81 (s, 1H, Ar-H), 6.90 (d, J = 8.2 Hz, 1H, Ar-H), 7.11 (d, J = 7.2 Hz, 1H, Ar-H), 7.25–7.35 (m, 1H, Ar-H) 7.28 (d, J = 8.2 Hz), 7.24 (br s, N–H), 8.90 (br s, N–H), 9.15 (s, 1H, OH); 13C NMR (50 MHz, DMSO-d6): δ 174.5, 165.2, 157.2, 144.8, 144, 129, 117.3, 114.9, 113.6, 102.3, 59.5, 54.7, 17.5, 13.9; EIMS: m/z [M+1]+: 292.
4.3 4-(3Hydroxy-phenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylicacid ethyl ester (4a-1)
Mp 180–181 °C; IR (KBr): 3512, 3352, 3244, 3119, 2980, 1718, 1678, 1600, 1460, 1229, 1094, 872, 779 cm−1; 1H NMR (200 MHz, DMSO-d6): δ 1.12 (t, 3H, J = 7.2 Hz, CH3), 2.24 (s, 3H, CH3), 3.99 (q, 2H, J = 7.2 Hz, OCH2–CH3), 5.07 (d, 1H, J = 3.0 Hz, CH-Ar), 6.61–6.68 (m, 3H, Ar-H), 7.09 (t, 1H, J = 8.0 Hz, Ar-H), 7.68 (s, 1H, NH), 9.15 (s, 1H, OH), 9.35 (s, 1H, NH); 13C NMR (50 MHz, DMSO-d6): δ 165.8, 157.8, 152.7, 148.5, 146.7, 129.7, 117.3, 114.6, 113.5, 99.9, 59.7, 54.3, 18.2,14.6; EIMS m/z [M+1]+: 277.11.
4.4 4-(3,4-Dimethoxy-phenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylicacid ethyl ester (4b-1)
Mp 171–173 °C; IR (KBr): 3350, 3220, 3190, 2984, 1668, 1650, 1620 cm−1; 1H NMR (200 MHz, DMSO-d6): δ 1.15(t, J = 8.2 Hz, 3H OCH2CH3), 2.14(s, 3H, CH3), 3.86 (s, 6H, 2×OCH3), 4.01(q, J = 8.2 Hz, 2H, OCH2CH3), 5.20(d, J = 3.0 Hz, 1H, CH-Ar), 6.78–6.82 (m,3H, Ar-H), 7.15(br s, N–H), 8.90(br s, N–H); 13C NMR (50 MHz, DMSO-d6): δ 164.6, 152.7, 152.1, 147.6, 147.1, 136.3, 117.5, 110.2, 109.2, 98.5, 58.5, 54.9, 53.2, 24.7, 14.0; EIMS: m/z [M+1]+: 321.
4.5 4-(4-Methoxy-phenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylicacid ethyl ester (4c-1)
Mp 201–202 °C; IR (KBr): 3223, 3095, 2929, 2833, 1710, 1655, 1512 cm−1; 1H NMR (200 MHz, DMSO-d6): δ 1.15(t, J = 7.2 Hz, 3H CH3), 2.24 (s, 3H, CH3), 3.80 (s, 3H, OCH3), 4.01 (q, J = 8.2 Hz, 2H, OCH2CH3), 5.18 (d, J = 3.0 Hz, 1H, CH-Ar), 6.88 (d, J = 8.2 Hz, 2H, Ar-H), 7.28 (d, J = 8.2 Hz), 7.24 (br s, N–H), 8.90(br s, N–H); 13C NMR (50 MHz, DMSO-d6): δ 165, 158.8, 152, 147.7, 137, 127.1, 113.7, 97.8, 58.6, 54.6, 53.4, 17.6, 13.9; EIMS: m/z [M+1]+: 291.
4.6 4-(4Chloro-phenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylicacid ethyl ester (4d-1)
Mp 217–218 °C; IR (KBr): 3237, 3117, 2978, 1701, 1647, 1460, 1288, 1221, 1088, 781 cm−1; 1H NMR (200 MHz, DMSO-d6): δ 1.09 (t, 3H, J = 7.2 Hz, OCH2–CH3), 2.25 (s, 3H, CH3), 3.98 (q, 2H, J = 7.2 Hz, OCH2–CH3), 5.14 (d, 1H, J = 3.0 Hz, CH-Ar), 7.25 (d, 2H, J = 8.4 Hz, Ar-H), 7.39 (d, 2H, J = 8.4 Hz, Ar-H), 7.77 (s, 1H, NH), 9.24 (s, 1H, NH); 13C NMR (50 MHz, DMSO-d6): δ 165.7 152.4, 149, 144.3, 132.2, 128.9, 128.6, 99.3, 59.7, 53.9, 18.3, 14.5; EIMS: m/z [M+1]+ 295.08.
4.7 4-(2Chloro-phenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylicacid ethyl ester (4e-1)
Mp 223–224 °C; IR (KBr): 3354, 3223, 3107, 2978, 1694, 1639, 1450, 1368, 1230, 1098, cm−1;1H NMR (200 MHz, DMSO-d6): δ 0.97 (t, 3H, J = 7.2 Hz, CH3). 2.28 (s, 3H, CH3), 3.87 (q, 2H, J = 7.2 Hz, OCH2–CH3), 5.61 (d, 1H, J = 2.8 Hz, CH-Ar), 7.24–7.40 (m, 4H, Ar-H), 7.68 (s, 1H, NH), 9.25 (s, 1H, NH); 13C NMR (50 MHz, DMSO-d6): δ 165.4, 151.8, 149.8, 142.2, 132.1, 129.8, 129.5, 129.2, 128.2, 98.3, 59.5, 51.9, 18.1, 14.4, EIMS: m/z [M+1]+: 295.08.
4.8 4-(2,4-Dimethoxy-phenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylicacid ethyl ester (4f-1)
Mp 200–202 °C; IR (KBr): 3223, 3095, 2929, 2833, 1710, 1655, 1512 cm−1; 1H NMR (200 MHz, DMSO-d6): δ 1.15 (t, J = 7.2 Hz, 3H CH3), 2.24 (s, 3H, CH3), 3.81 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 4.01 (q, J = 8.2 Hz, 2H, OCH2CH3), 5.18 (d, J = 3.2 Hz, 1H, CH-Ar), 6.38 (d, J = 7.8 Hz, 2H, Ar-H), 7.28 (s, 1H, Ar-H), 6.80 (br s, N–H), 6.90 (d, J = 7.8 Hz, 2H, Ar-H), 9.00 (br s, N–H); 13C NMR (50 MHz, DMSO-d6); δ 164.6, 153.7, 152.1, 148.6, 147.1, 136.3, 116.5, 112.2, 105.2, 98.5, 59.5, 54.9, 53.2, 23.7, 13.0. EIMS: m/z [M+1]+: 320.
4.9 4-(3-Nitro-phenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid ethyl ester (4g-1)
Mp 229–230 °C; IR (KBr): 3238, 3123, 2986, 1730, 1705, 1645, 1522, 1348, 1219, 1096, 854, 783 cm−1; 1H NMR (200 MHz, DMSO-d6): δ 1.10 (t, 3H, J = 7.2 Hz, CH3), 2.27 (s, 3H, CH3), 3.99 (q, 2H, J = 7.2 Hz, OCH2–CH3), 5.27 (d, 1H, J = 3.0 Hz, CH-Ar), 7.50 (d, 2H, J = 8.6 Hz, Ar-H), 7.89 (s, 1H, NH), 8.22 (d, 2H, J = 8.6 Hz, Ar-H), 9.35 (s, 1H, NH); 13C NMR (50 MHz, DMSO-d6): δ 165.5, 152.5, 152.2149.9147.2 128.1, 124.3, 98.6, 59.9, 54.1, 18.3,14.5; EIMS m/z [M+1]+: 306.10.
4.10 4-(4-Hydroxy-phenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid ethyl ester (4h-1)
Mp 234–235 °C; IR (KBr): 3235, 3113, 2955, 1703, 1647, 1514, 1456, 1279, 1221, 1088, 837, 791 cm−1; 1H NMR (200 MHz, DMSO-d6): δ 1.10 (t, 3H, J = 7.2 Hz, CH3); 2.25 (s, 3H, CH3), 3.98 (q, 2H, J = 7.2 Hz, OCH2–CH3), 5.09 (d, 1H, J = 3.0 Hz, CH-Ar), 6.87 (d, 2H, J = 8.6 Hz, Ar-H), 7.15 (d, 2H, J = 8.6 Hz, Ar-H), 7.67 (s, 1H, NH), 9.13 (s, 1H, NH); 13C NMR (50 MHz, DMSO-d6): δ 166.8, 157.9, 150.6, 147.5, 136.5, 125.9, 112.2, 100.0, 56.5, 53.8, 18.2, 15.6; EIMS m/z [M+1]+: 277.12.
4.11 4-(3,4,5-Trimethoxy-phenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid ethyl ester (4i-1)
Mp 171–173 °C; IR (KBr): 3350, 3220, 3190, 2984, 1668, 1650, 1620 cm−1;1H NMR (200 MHz, DMSO-d6): δ 1.15 (t, J = 7.2 Hz, 3H OCH2CH3), 2.14 (s, 3H, CH3), 3.86 s, 9H, 3xOCH3), 4.01 (q, J = 7.2 Hz, 2H, OCH2CH3), 5.20 (d, 1H, J = 3.0 Hz, CH-Ar), 6.78–6.82 (m, 3H, Ar-H), 7.15 (br s, N–H), 8.90 (br s, N–H); 13C NMR (50 MHz, DMSO-d6): δ 164.6152.3, 152.7, 152.1, 147.6, 147.1, 136.3, 117.5, 110.2, 109.2, 98.5, 58.5, 54.9, 53.2, 24.7, 14.0; EIMS: m/z[M+1]+: 320.
4.12 4Phenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid ethyl ester (4j-1)
Mp 202–204 °C; IR (KBr): 3256, 3121, 2945, 1730, 1703, 1647, 1464, 1290, 1226, 1090, 756 cm−1; 1H NMR (200 MHz, DMSO-d6): δ 1.09 (t, 3H, J = 7.0 Hz, CH3); 2.25 (s, 3H, CH3), 3.98 (q, 2H, J = 7.0 Hz, OCH2–CH3), 5.15 (d, 1H, J = 3.2 Hz, CH-Ar), 7.21–7.35 (m, 5H, Ar-H), 7.73 (s, 1H, NH), 9.19 (s, 1H, NH); 13C NMR (50 MHz, DMSO-d6): δ 165.8, 152.6, 148.8, 145.3, 128.8, 127.7, 126.7, 99.7, 59.6, 54.4, 18.2 14.5; EIMS m/z [M+1]+: 261.12.
References
- Ind. J. Chem.. 2007;46:1690.
- J. Med. Chem.. 1990;33:2629.
- Tetrahedron Lett.. 2007;48:4569.
- J. Med. Chem.. 1991;34:806.
- Tetrahedron Lett.. 2009;50:2889.
- Synth. Commun.. 2009;39:1801.
- J. Iran. Chem. Soc.. 2008;5:62.
- J. Org. Chem.. 2000;65:6270.
- Bioorg. Med. Chem. Lett.. 2006;16:1418.
- Eur. J. Med. Chem.. 2010;45:367.
- Bioorg. Med. Chem. Lett.. 2006;16:3504.
- Tetrahedron Lett.. 2008;49:6119.
- Isocyanide based multi component reactions in combinatorial chemistry comb. Chem. High Throughput Screen.. 1998;1:1.
- [Google Scholar]
- Chem. Rev.. 2006;106:17. For reviews concerning multi component condensation reactions see: And references cited therein
- Bioorg. Med. Chem. Lett.. 2007;15:6474.
- J. Am. Chem. Soc.. 1932;54:3751.
- Phosphorus Sulfur Silicon. 2009;184:2333.
- Eur. J. Med. Chem.. 2004;39:777.
- Tetrahedron Lett.. 2001;42:5917.
- J. Iran. Chem. Soc.. 2009;6:514.
- Tetrahedron Lett.. 2011;52:80.
- Tetrahedron. 1993;49:6937.
- Molecules. 1998;3:1.
- Acc. Chem. Res.. 2000;33:879.
- Eur. J. Med. Chem.. 2000;35:1043.
- Bioorg. Med. Chem. Lett.. 2008;18:278.
- J. Chem. Soc., Perkin Trans. 1 2002:1845.
- Mol. Divers.. 2009;13:5. For reviews on the Biginelli reaction, see: And references cite therein
- Tetrahedron Lett.. 2001;42:7873.
- J. Org. Chem.. 2000;65:3864.
- Chem. Heterocycl. Comp.. 1970;6:501.
- Green Chem. Lett. Rev.. 2010;3:329.
- Tetrahedron Lett.. 2003;44:3305.
- Bioorg. Med. Chem. Lett.. 2006;16:2463.
- J. Chem. Soc., Chem. Commun. 1995:1369.
- Tetrahedron.. 2008;64:5023.
- Org. Process Res. Devel.. 2002;6:817.
- Synth. Commun.. 2006;36:1503.
- J. Med. Chem.. 1992;35:3254.
- J. Med. Chem.. 1995;38:119.
- Target oriented and diversity–oriented organic synthesis on drug discovery. Science. 2000;287:1964.
- [Google Scholar]
- Chem. Heterocycl. Compd.. 1998;34:848.
- Arab. J. Chem.. 2016;9:S846.
- J. Org. Chem.. 2003;68:587.
- Synth. Commun.. 2005;35:2645.
- Mendeleev Commun.. 2004;14:210.
- Valverde, M.G., Dallinge, D., Kappe C.O., 2001. Synlett 741.
- Tetrahedron Lett.. 2005;46:6037.
- J. Chem. Soc., Perkin Trans. 1 2001:1939.
- Bioorg Med. Chem. Lett.. 2007;17:3508.
- Synth. Commun.. 2009;39:2230.
- J. Org. Chem.. 2010;75:1162.
- Synth. Commun.. 2004;34:3167.
- Bioorg. Med. Chem.. 2006;14:8582.